Neural Development
Neural development describes the growth and development of the nervous system starting from embryogenesis and continuing throughout life.
Neural Development Products Targets
- FGFR (5)
- GABAB Receptor (28)
- Others (13)
- Stem Cell Signaling (27)
- Stem Cell Proliferation (25)
- Reprogramming (17)
- Nucleoside Transporter (5)
- Glycine Transporter (6)
- GABA (10)
- Cannabinoid Transporter (10)
- Acetylcholine Transporter (1)
- D4 Receptor (12)
- PORCN (4)
- beta-catenin (13)
- Casein Kinase 1 (7)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- NOP Receptor (21)
- Mu-Opioid Receptors (15)
- Kappa Opioid Receptors (14)
- AMPA Receptor (45)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- GPR55 (8)
- CB2 Receptor (6)
- CB1 Receptor (17)
- Nicotinic (α7) Receptor (25)
- Nicotinic (α4β2) Receptor (14)
- D3 Receptor (12)
- Vesicular Monoamine Transporter (4)
- NMDA Receptor (87)
- Kainate Receptor (22)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Glutamate Transporter (18)
- Dopamine Transporter (20)
- Tankyrase (5)
- Adrenergic Transporter (23)
- 5-HT Transporter (30)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Stem Cell Differentiation (54)
- Delta opioid receptor (16)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
- Hedgehog Signaling (15)
- Cancer Stem Cell (9)
Products for Neural Development - Page 77
- Cat.No. Product Name Information/Activity
-
BCC3981
SW033291
SW033291 is a potent and high-affinity inhibitor of 15-PGDH with a Ki of 0.1 nM. SW033291 increases prostaglandin PGE2 levels in bone marrow and other tissues. SW033291 also promotes tissue regeneration.
-
BCC2016
Troglitazone
Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.
-
BCC8051
WH-4-023
WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC50 of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.
-
BCC2121
17-AAG (KOS953)
Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90. Tanespimycin (17-AAG) depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin (17-AAG) also downregulates the stk38 gene expression.
-
BCC2466
Alexidine dihydrochloride
Alexidine dihydrochloride is an anticancer agent that targets a mitochondrial tyrosine phosphatase, PTPMT1, in mammalian cells and causes mitochondrial apoptosis. Alexidine dihydrochloride has antifungal and antibiofilm activity against a diverse range of fungal pathogens.
-
BCC4447
Plerixafor 8HCl (AMD3100 8HCl)
Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.
-
BCC8002
BIO 5192
327613-57-0
-
BCC6076
BIO-acetoxime
BIO-acetoxime (BIA) is a potent and selective GSK-3 inhibitor, with IC50s of both 10 nM for GSK-3α/β. BIO-acetoxime has anticonvulsant and anti-infection activity.
-
BCC3781
Flurbiprofen
Flurbiprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity.
-
BCC5102
IWR-1-endo
IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway.
